- Company selected to present at Informa's Therapeutic Area Partnerships meeting at 1:30 pm ET on Thursday, November 20 in Boston
WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its investigational compound RAD1901.
Gary Hattersley, Ph.D., Chief Scientific Officer at Radius Health, is scheduled to present at Informa's Therapeutic Area Partnerships meeting taking place November 19-21 at the Hyatt Regency in Boston. Dr. Hattersley's presentation on the investigational drug RAD1901, a SERD being developed for potential use in the treatment of metastatic breast cancer, including breast cancer brain metastases, will occur at 1:30 pm ET on Thursday, November 20 within Track 3 (Oncology).
Products selected as one of the Most Interesting Oncology Projects to Watch have met a range of criteria; including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications.
"Selected products have been screened using a strict set of judging criteria for the Top 10 award and represent what Informa and Kantar Health consider among the most attractive opportunities the industry has to offer," said Bill Bagwell, General Manager, Oncology, Kantar Health. "As an industry leader in oncology strategic research and consulting, it is exciting to give these companies exposure to potential investors, partners and acquirers."
"We welcome the opportunity to discuss the clinical development of our investigational candidate, RAD1901, at Informa's Therapeutic Area Partnership meeting," said President and CEO, Robert Ward of Radius Health. "We are particularly pleased that Radius Health has been selected by Informa and Kantar Health staff as having one of the top ten most interesting oncology projects."
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.comSource:Radius Health